Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Should risky treatments be reserved for secondary prevention? Theoretical considerations regarding risk-benefit tradeoffs.

Westover MB, Eiseman NA, Bianchi MT. Should risky treatments be reserved for secondary prevention? Theoretical considerations regarding risk-benefit tradeoffs. J Clin Epidemiol. 2012 Aug; 65(8):877-86.

View in: PubMed

Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.